301688.SZ
C格林生物
SZSE · C 制造业 · CN
CNY 41.19
Year over year
Reported trailing growth
- Revenue
- +16.9%
- EBITDA
- —
- EBIT
- +12.7%
- EPS
- —
- Free cash flow
- +221.7%
- Operating cash flow
- +3.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +19.4%
- EBITDA
- +34.1%
- EBIT
- +39.3%
- Net income
- +38.0%
- EPS
- +38.1%
- Free cash flow
- +742.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026